Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

ClinicalTrials.gov ID: NCT06138639

Public ClinicalTrials.gov record NCT06138639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males With Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dystrophy. There will be 5 cohorts in this study. Cohort 1 will include participants 4 to \< 7 years of age. Cohort 2 will include participants 7 to \< 12 years of age. Cohort 3 will include participants 0 to \< 4 years of age. Cohort 4 will include participants 12 to \< 18 years of age. Cohort 5 will include participants 10 to \< 18 years of age. Initiation of participant enrollment in Cohorts 4 and 5 will be subject to the accrual of safety and efficacy data from Cohorts 1-3. All participants will receive SGT-003 and will be enrolled in the study for 5 total years for long-term follow up.

Study identification

NCT ID
NCT06138639
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Solid Biosciences Inc.
Industry
Enrollment
60 participants

Conditions and interventions

Interventions

Genetic

Eligibility (public fields only)

Age range
0 Years to 17 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 5, 2024
Primary completion
May 5, 2027
Completion
May 5, 2031
Last update posted
Jul 7, 2026

2024 – 2031

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
Arkansas Children's Hospital Little Rock Arkansas 72202 Recruiting
University of California, Los Angeles Medical Center Los Angeles California 90095 Recruiting
University of California, Davis Sacramento California 95817 Recruiting
University of California San Diego California 92037 Recruiting
Rare Disease Research Atlanta Georgia 30329 Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois 60611-2605 Recruiting
Washington University in St. Louis St Louis Missouri 63110 Recruiting
Nationwide Children's Hospital Columbus Ohio 43215 Recruiting
Oregon Health and Sciences University Portland Oregon 97239 Recruiting
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104 Recruiting
Children's Hospital of the King's Daughters Norfolk Virginia 23510 Recruiting
Seattle Children's Hospital Seattle Washington 98105 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06138639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 7, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06138639 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →